Related Experiment Videos
Pharmacokinetic interaction between nifedipine and propranolol
E Zylber-Katz1, M Turetz-Abramovitch, G Koren
1Department of Medicine A, Hadassah University Hospital, Jerusalem, Israel.
Fundamental & Clinical Pharmacology
|January 1, 1988
Summary
Coadministration of propranolol significantly increases nifedipine bioavailability and Cmax in healthy volunteers. This interaction is likely due to propranolol reducing the liver's first-pass metabolism of nifedipine.
Area of Science:
- Pharmacology
- Drug Interactions
- Clinical Pharmacokinetics
Background:
- Nifedipine is a widely used calcium channel blocker.
- Propranolol is a non-selective beta-adrenergic receptor antagonist.
- Understanding drug-drug interactions is crucial for safe and effective medication use.
Purpose of the Study:
- To investigate the pharmacokinetic interaction between nifedipine and propranolol.
- To determine the effect of propranolol on nifedipine bioavailability and clearance.
Main Methods:
- Single-dose pharmacokinetic study in 8 healthy volunteers.
- Comparison of nifedipine pharmacokinetics alone versus coadministered with propranolol.
- Analysis of key pharmacokinetic parameters including Cmax, AUC, half-life, and clearance.
Main Results:
- Coadministration with propranolol significantly increased nifedipine's mean Cmax (73.9 to 115.7 ng/ml) and AUC0-infinity (287.1 to 363.0 (micrograms.hr)/l).
- Nifedipine bioavailability increased significantly (P < 0.01) when coadministered with propranolol.
- Propranolol did not significantly alter nifedipine's half-life or volume of distribution, but systemic clearance tended to decrease.
Conclusions:
- Propranolol significantly enhances nifedipine bioavailability.
- The interaction is likely mediated by a reduction in hepatic first-pass clearance of nifedipine due to altered hepatic blood flow induced by propranolol.
- This interaction has implications for nifedipine dosing and patient management.